Home » Stocks » OBSV

ObsEva SA (OBSV)

Stock Price: $3.90 USD 0.05 (1.30%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
After-hours: $3.88 -0.02 (-0.51%) Mar 2, 7:58 PM
Market Cap 256.16M
Revenue (ttm) 16,000
Net Income (ttm) -108.79M
Shares Out 45.48M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $3.90
Previous Close $3.85
Change ($) 0.05
Change (%) 1.30%
Day's Open 3.94
Day's Range 3.82 - 4.03
Day's Volume 1,487,194
52-Week Range 1.63 - 6.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

GlobeNewsWire - 2 weeks ago

GlobeNewsWire - 2 weeks ago

InvestorPlace - 3 weeks ago

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALNA, ALRN, MBIO, MCHX, MDWD, RWLK
InvestorPlace - 1 month ago

There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.

Other stocks mentioned: ABML, GHSI, NMGRF, SB, ISR, ZOM
GlobeNewsWire - 1 month ago

Seeking Alpha - 1 month ago

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT, HASI, HMHC, LXRX, MNKD, NKTR, NNOX, PSNL, PTY, ROAD, SGRY, SP, TAK, UTF, XRM
Zacks Investment Research - 1 month ago

Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.

InvestorPlace - 1 month ago

ObsEva (OBSV) stock is soaring higher on Friday as shares see heavy trading despite there not being any noteworthy news today. The post OBSV Stock: 7 Things for ObsEva Investors to Know Before...

InvestorPlace - 1 month ago

In the last round, 36% of recipients saved the money, If you're planning the same with the second payment, here are seven stocks to buy with your stimulus check. The post 7 Stocks to Buy With ...

Other stocks mentioned: APHA, JPM, LMT, NEM, NIO, STPK
GlobeNewsWire - 1 month ago

GlobeNewsWire - 1 month ago

Geneva, Switzerland and Boston, MA – January 7, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's repro...

GlobeNewsWire - 1 month ago

Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improv...

GlobeNewsWire - 2 months ago

 PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT])

GlobeNewsWire - 3 months ago

Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to impro...

Zacks Investment Research - 3 months ago

ObsEva (OBSV) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids

GlobeNewsWire - 3 months ago

Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy

GlobeNewsWire - 3 months ago

Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to impr...

GlobeNewsWire - 3 months ago

 Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to impr...

GlobeNewsWire - 4 months ago

 Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to impr...

GlobeNewsWire - 4 months ago

 Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's ...

GlobeNewsWire - 4 months ago

Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's r...

GlobeNewsWire - 5 months ago

 ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Lou...

GlobeNewsWire - 5 months ago

 GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercial...

GlobeNewsWire - 6 months ago

 Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s r...

GlobeNewsWire - 6 months ago

 Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids

GlobeNewsWire - 7 months ago

 Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s rep...

GlobeNewsWire - 7 months ago

 PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24

GlobeNewsWire - 8 months ago

 ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will pres...

GlobeNewsWire - 8 months ago

 ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise ...

GlobeNewsWire - 8 months ago

Geneva, Switzerland and Boston, MA – June 9, 2020  - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel ...

GlobeNewsWire - 8 months ago

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproduc...

Seeking Alpha - 9 months ago

ObsEva Has A Promising Candidate For An Unmet Need - Behind The Idea

GlobeNewsWire - 9 months ago

 ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financia...

Zacks Investment Research - 10 months ago

ObsEva (OBSV) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

GlobeNewsWire - 10 months ago

 Geneva, Switzerland and Boston, MA – Tuesday 14, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization...

GlobeNewsWire - 10 months ago

 Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s rep...

GlobeNewsWire - 11 months ago

 GENEVA, Switzerland and BOSTON, MA (March 23, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s repro...

Seeking Alpha - 11 months ago

ObsEva's (OBSV) CEO Ernest Loumaye on Q4 2019 Results - Earnings Call Transcript

GuruFocus - 1 year ago

Wall Street analysts recommend increasing holdings in EQT Corporation (NYSE:EQT) and ObsEva SA (NASDAQ:OBSV), even though their share prices have dropped more than 59% in the past year through...

Other stocks mentioned: EQT
Market Watch - 1 year ago

Shares of ObsEva gained 22% in premarket trading on the news that the company' s experimental treatment for women with uterine fibroids met its primary and secondary endpoints in a Phase 3 tr...

Zacks Investment Research - 1 year ago

ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

ObsEva SA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Investment Research - 1 year ago

ObsEva SA (OBSV) delivered earnings and revenue surprises of 23.17% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

 ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that the Phase 3 clini...

GlobeNewsWire - 1 year ago

 Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of no...

GlobeNewsWire - 1 year ago

Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids w...

GlobeNewsWire - 1 year ago

Geneva, Switzerland and Boston, MA – October 9, 2019- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization o...

GlobeNewsWire - 1 year ago

Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of n...

About OBSV

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatme... [Read more...]

Industry
Biotechnology
IPO Date
Jan 26, 2017
CEO
Ernest Loumaye
Employees
53
Stock Exchange
NASDAQ
Ticker Symbol
OBSV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ObsEva stock is "Buy." The 12-month stock price forecast is 11.67, which is an increase of 199.23% from the latest price.

Price Target
$11.67
(199.23% upside)
Analyst Consensus: Buy